Myelogenous Leukemia CML And The Potential For Ribozyme Therapy

CHRONIC MYELOGENOUS LEUKEMIA (CML) AND THE POTENTIAL FOR RIBOZYME THERAPY 

In some cytogenetic abnormalities, such as certain leukemias, chimeric fusion mRNAs connecting strange exons result from reciprocal chromosomal translocations and cause abnormalities. For the design of ribozymes that can disrupt such chimeric RNAs, it is necessary to target the junction sequence. Otherwise, normal mRNAs that share part ofthe chimeric RNA sequence will also be cleaved by the ribozyme, with resultant damage to the host cells. 

---